Please login to the form below
Juvederm
This page shows the latest Juvederm news and features for those working in and with pharma, biotech and healthcare.
Botox strength bolsters Allergan ahead of AbbVie takeover
The US specialised therapeutics business – which include Botox – posted just 0.7% growth in the quarter to $1.82bn as medical aesthetics products Juvederm and Restasis posted sales declines.
Latest news
-
Allergan adds Zeltiq to M&A roster in $2.48n deal
The division grew 40% to $1.62bn last year, with the sales increase driven by Botox and the Juvederm dermal filler range.
-
Allergan buys regenerative medicine firm LifeCell for $2.9bn
Those are headed by blockbuster wrinkle treatment Botox but also include Kybella - bought along with Kythera last year for $2.1bn - for reducing double chins and dermal filler Juvederm.
-
Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera
sales channels already in place for wrinkle treatment Botox and its dermal filler products Voluma, JuveDerm and SkinMedica.
-
Communiqué Awards 2009: Results
Finalists:. Chandler Chicco Agency and Allergan with Creating a Positive Media Environment for the European Launch of Juvéderm ULTRA.
-
Gaining ground
US. Hyaluronan injections. JuvedÈrm Ultra and JuvÈderm Ultra Plus (Allergan Canada).
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Pharma deals during November 2012
SkinMedica's topical aesthetics skincare business includes a variety of "physician dispensed" non-prescription and prescription products that sit more comfortably with Allergan's “wrinkle reducers” Botox and Juvederm.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
